Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease
NCT00532350 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22
Last updated 2020-12-19
Summary
This study will assess the safety and tolerability of QAT370 compared to tiotropium in patients with COPD.
Conditions
Interventions
- DRUG
-
QAT370
- DRUG
- DRUG
-
Tiotropium
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis · Investigative site
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 40 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-07-31
- Completion
- 2008-01-31
Countries
- Germany
Study Locations
More Related Trials
-
A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
NCT01972776 ·Status: TERMINATED ·Phase: PHASE2
-
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00422604 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01372410 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01613326 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01285492 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01574651 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease
NCT00515502 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control
NCT01715311 ·Status: WITHDRAWN ·Phase: PHASE4
-
Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD
NCT00274040 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
NCT00749411 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity
NCT00274573 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
NCT01513460 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.
NCT00783406 ·Status: COMPLETED ·Phase: PHASE2
-
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00929110 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01202188 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease
NCT00279019 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD
NCT00530842 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172469 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00570778 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00545311 ·Status: COMPLETED ·Phase: PHASE1
-
Tiotropium and Salmeterol PK Study in COPD Patients
NCT00673478 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02238119 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01490125 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD
NCT00239460 ·Status: COMPLETED ·Phase: PHASE3